Listed

Iovance Biotherapeutics, Inc.

IOVANasdaqCIK 1425205HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$99.3mRevenue, Q2 FY2026, three months to 2026-06-30$99.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$99.3mRevenue, Q2 FY2026, three months to 2026-06-30$99.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure+65.7% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−52.3%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$51.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Revenue: $99.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure+137.5 pts on a year earlier
  • Net margin−47.6%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$47.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Revenue: $99.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure+138.6 pts on a year earlier
  • Diluted EPS−$0.11Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure+66.7% on a year earlier
  • Free cash flow−$66.3mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$60.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-091716. Derived: 6-month figure less the 3-month figure.Capital expenditure: $5.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-091716. Derived: 6-month figure less the 3-month figure.Report this figure+11.5% on a year earlier

Last eight quarters

Full statements
Revenue$99.3mOperating margin −52.3%
Diluted EPS−$0.11, Q2 FY2026
Free cash flow−$66.3m, Q2 FY2026
Iovance Biotherapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m58.6Revenue, Q3 FY2024, three months to 2024-09-30$58.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107470.Report this figure73.7Revenue, Q4 FY2024, three months to 2024-12-31$73.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Report this figure49.3Revenue, Q1 FY2025, three months to 2025-03-31$49.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Report this figure60.0Revenue, Q2 FY2025, three months to 2025-06-30$60.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure67.5Revenue, Q3 FY2025, three months to 2025-09-30$67.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107470.Report this figure86.8Revenue, Q4 FY2025, three months to 2025-12-31$86.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Report this figure71.4Revenue, Q1 FY2026, three months to 2026-03-31$71.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Report this figure99.3Revenue, Q2 FY2026, three months to 2026-06-30$99.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(152.1%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$89.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107470.Revenue: $58.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107470.Report this figure(117.5%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$86.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Revenue: $73.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Report this figure(245.8%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$121.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Revenue: $49.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Report this figure(189.8%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$113.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Revenue: $60.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure(140.7%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$94.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107470.Revenue: $67.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107470.Report this figure(84.7%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$73.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Revenue: $86.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Report this figure(113.5%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$81.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Revenue: $71.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Report this figure(52.3%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$51.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Revenue: $99.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure
Net margin%(142.7%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$83.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107470.Revenue: $58.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107470.Report this figure(106.6%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$78.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Revenue: $73.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Report this figure(235.5%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$116.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Revenue: $49.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Report this figure(186.2%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$111.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Revenue: $60.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure(135.3%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$91.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107470.Revenue: $67.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107470.Report this figure(82.9%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$71.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Revenue: $86.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Report this figure(110.7%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$79.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Revenue: $71.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Report this figure(47.6%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$47.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Revenue: $99.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure
Diluted EPS$ per share(0.28)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0001558370-24-014905.Report this figurenot reported (Diluted EPS not reported)(0.36)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Report this figure(0.33)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)(0.19)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Report this figure(0.11)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091716.Report this figure
Free cash flow$m(61.3)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$59.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107470. Derived: 9-month figure less the 6-month figure.Capital expenditure: $2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107470. Derived: 9-month figure less the 6-month figure.Report this figure(77.5)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$73.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Capital expenditure: $4.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Report this figure(110)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$103.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Capital expenditure: $6.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Report this figure(74.9)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$67.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-091716. Derived: 6-month figure less the 3-month figure.Capital expenditure: $7.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-091716. Derived: 6-month figure less the 3-month figure.Report this figure(89.5)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$78.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107470. Derived: 9-month figure less the 6-month figure.Capital expenditure: $10.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107470. Derived: 9-month figure less the 6-month figure.Report this figure(61.9)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$52.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Capital expenditure: $9.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001104659-26-018899. Derived: 12-month figure less the 9-month figure.Report this figure(78.7)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$72.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Capital expenditure: $6.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-056778.Report this figure(66.3)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$60.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-091716. Derived: 6-month figure less the 3-month figure.Capital expenditure: $5.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-091716. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$263.5mOperating margin −153.1%
Diluted EPS−$1.09, FY2025
Free cash flow−$336.2m, FY2025
Iovance Biotherapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)1.2Revenue, FY2023, twelve months to 2023-12-31$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure164Revenue, FY2024, twelve months to 2024-12-31$164.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure264Revenue, FY2025, twelve months to 2025-12-31$263.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)(38735.0%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$460.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018899.Revenue: $1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure(240.9%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$395.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018899.Revenue: $164.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure(153.1%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$403.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018899.Revenue: $263.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)(37345.4%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$444.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018899.Revenue: $1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure(226.8%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$372.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018899.Revenue: $164.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure(148.4%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$391.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018899.Revenue: $263.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure
Diluted EPS$ per share(2.23)Diluted EPS, FY2021, twelve months to 2021-12-31−$2.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-28, accession 0001558370-24-002036.Report this figure(2.49)Diluted EPS, FY2022, twelve months to 2022-12-31−$2.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0001558370-25-001834.Report this figure(1.89)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.89 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure(1.28)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure(1.09)Diluted EPS, FY2025, twelve months to 2025-12-31−$1.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure
Free cash flow$m(266)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$227.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-28, accession 0001558370-24-002036.Capital expenditure: $37.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-28, accession 0001558370-24-002036.Report this figure(313)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$292.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0001558370-25-001834.Capital expenditure: $20.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0001558370-25-001834.Report this figure(384)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$361.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001104659-26-018899.Capital expenditure: $22.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure(364)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$353.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001104659-26-018899.Capital expenditure: $11.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure(336)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$302.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001104659-26-018899.Capital expenditure: $33.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001104659-26-018899.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Iovance Biotherapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$153.7m36,957,681Added+5,877,176
MHR FUND MANAGEMENT LLC2026-06-30$120.5m28,967,103Unchanged
STATE STREET CORP2026-06-30$101.8m24,478,268Added+7,030,160
TWO SIGMA INVESTMENTS, LP2026-06-30$79.1m19,010,697Added+5,323,264
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$75.7m18,204,248Added+1,586,511
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$59.9m14,388,999Added+2,688,155
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$43.0m10,324,826Added+1,752,228
MILLENNIUM MANAGEMENT LLC2026-06-30$35.5m8,525,919Reduced−888,373
DIMENSIONAL FUND ADVISORS LP2026-06-30$26.9m6,460,449Added+3,814,747
Palo Alto Investors LP2026-06-30$22.0m5,296,209Reduced−1,053,354

Recent filings

All 1,016 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Iovance Biotherapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2917:00 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-120261
2026-10-0517:00 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-113763
2026-09-2907:05 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-111583
2026-08-0617:30 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-092145
2026-08-0609:15 ET10-QQuarterly reportPeriod 2026-06-300001104659-26-091716
2026-08-0607:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-26-091619
2026-07-0217:01 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-080409
2026-06-1017:01 ET8-K5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-072408
2026-05-0709:18 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-26-056782
2026-05-0709:16 ET10-QQuarterly reportPeriod 2026-03-310001104659-26-056778

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 24, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1425205
Tickers
IOVA
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer
Former names
Lion Biotechnologies, Inc. (to 2017-06-05); Genesis Biopharma, Inc (to 2013-09-23); FREIGHT MANAGEMENT CORP (to 2010-03-08)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:02 ET. Listed shows no prices and gives no investment advice.